|Free Dividend Report|
|Stock Splits Calendar|
|ABEO Stock Split History|
|Preferred Stock Newsletter|
|ABEO Options Chain|
|Stock Message Boards|
Abeona Therapeutics (ABEO) has 1 split in our ABEO split history database. The split for ABEO took place on July 05, 2022. This was a 1 for 25 reverse split, meaning for each 25 shares of ABEO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split.
When a company such as Abeona Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ABEO split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Abeona Therapeutics shares, starting with a $10,000 purchase of ABEO, presented on a split-history-adjusted basis factoring in the complete ABEO split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-9.67%|
|About Abeona Therapeutics|
|Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Co.'s primary clinical program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, which is in the pivotal Phase 3 VIITAL clinical trial. Co. is developing additional adeno-associated virus (AAV)-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that Co. has licensed from University of North Carolina at Chapel Hill, and internal AAV vector research programs. According to our ABEO split history records, Abeona Therapeutics has had 1 split.|
|ABEO Split History Table|
|07/05/2022||1 for 25|
|Healthcare Stock Splits|
|ABEO is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: ABEO shares outstanding history